Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a product name.
REQUEST A FREE TRIAL
Product
Deals
Articles
BioCentury
|
Jun 2, 2017
Clinical News
Medicines Co., Alnylam to begin Phase III program of inclisiran
Read More
BioCentury
|
Feb 23, 2017
Clinical News
Inclisiran: extension study started
Read More
BioCentury
|
Feb 1, 2017
Clinical News
Inclisiran: Ph II ORION-2 started
Read More
BioCentury
|
Dec 31, 2016
Finance
Delivering takeouts
25th annual Buyside View sees investors eyeing mid-cap M&A targets in 2017
Read More
BioCentury
|
Nov 18, 2016
Clinical News
Inclisiran: Additional Ph II ORION-1 data
Read More
BioCentury
|
Nov 15, 2016
Clinical News
Medicines Co., Alnylam PCSK9 heading for Phase III
Read More
BioCentury
|
Nov 10, 2016
Clinical News
MDCO-216: Development discontinued
Read More
BioCentury
|
Nov 9, 2016
Clinical News
Medicines Co. ending CV program MDCO-216
Read More
BioCentury
|
Nov 3, 2016
Clinical News
PCSK9si: Interim Ph II data
Read More
BioCentury
|
Oct 10, 2016
Finance
Program or platform?
Debating whether Alnylam's discontinued programs impact the rest of its pipeline
Read More
Items per page:
10
1 - 10 of 32